mavorixafor will enhance the level or influence of triazolam by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe. Keep track of for adverse results of delicate CYP3A4 substrates if coadministered with mavorixafor (a weak CYP3A4 inhibitor).  The estimated history risk of significant birth defects and miscarriage for the